Alnylam Pharmaceuticals Inc ALNY:NASDAQ (Common Stock)

LastDaily Change / % ChangeDividend YieldVolumeAvg Volume (10 day)
125.25 0.61   0.49%--1,147,602789.8K
Market data is delayed by at least 15 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Previous close 1/17/2018

Latest News Headlines for Alnylam Pharmaceuticals Inc

No News for Alnylam Pharmaceuticals Inc

Peers Information HelpALNY Alnylam Pharmaceuticals Inc vs. Peers

Alnylam Pharmaceuticals Inc
Nektar Therapeutics
bluebird bio Inc
Juno Therapeutics Inc
Neurocrine Biosciences, Inc.
Alnylam Pharmaceuticals Inc
Nektar Therapeutics
bluebird bio Inc
Juno Therapeutics Inc
Neurocrine Biosciences, Inc.
Alnylam Pharmaceuticals Inc
Nektar Therapeutics
bluebird bio Inc
Juno Therapeutics Inc
Neurocrine Biosciences, Inc.
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings

This report contains detailed information about the company's business finances and management.


Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).


collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open126.13
Previous Close125.25
Day High127.90
Day Low123.45
52 Week High11/2/2017 | 147.63
52 Week Low1/31/2017 | 35.98
% Off 52 Week High-15.16%
% Off 52 Week Low248.11%
Beta (5 Yr)2.68
Volatility Avg1/17/2018 | 71.75
10-Day Avg. Volume789,800
Market data is delayed by at least 15 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)9/30/2017 | -5.25
P/E Ratio9/30/2017 | --
Market CapLarge Cap | 12.32B
Shares Outstanding98.33M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short5.78M
Short Ratio8.4
Short % of Float6.66%
As of 12/29/2017
The performance data quoted represents past performance. Past performance does not guarantee future results. Current performance may be lower or higher than the performance quoted. Investment return and principal value of an investment will fluctuate and when redeemed, the investment may be worth more or less than their original cost.
The research, tools, and information provided will not include every security available to the public.